Does clinical management impact height potential in children with severe acquired hypothyroidism?

Research output: Contribution to journalArticle

11 Scopus citations


Background: Severe acquired hypothyroidism often results in significant height deficit due to rapid bone age advancement following treatment. Whether gradual correction of hypothyroidism and/or adjunctive growth-promoting therapies (GPTs) augment final adult height (FAH) is controversial. Objective: To investigate time to euthyroidism, pace of bone age advancement (ΔBA/ΔCA), and impact of GPTs on FAH. Methods and patients: Retrospective review of 21 children (10.1±3.0 years) with profound hypothyroidism. Results: Baseline bone age standard deviation score (SDS) was-4.1±1.8, whereas height SDS was-3.0±1.1. Average time to euthyroidism was 9.7 months (2.3-33.7 months). Average ΔBA/ΔCA was 2.3±0.9. Six of 13 patients at FAH received GPTs. No correlation was found between time to euthyroidism and rate of skeletal maturation. No difference in height outcome was seen between those who received GPTs and those who did not. Conclusions: Neither time to euthyroidism nor use of GPTs significantly affected height potential in our patients.

Original languageEnglish (US)
Pages (from-to)893-896
Number of pages4
JournalJournal of Pediatric Endocrinology and Metabolism
Issue number11-12
StatePublished - Dec 1 2011


  • bone age
  • growth failure
  • skeletal maturation

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Does clinical management impact height potential in children with severe acquired hypothyroidism?'. Together they form a unique fingerprint.

  • Cite this